Acelyrin

ACELYRIN, INC. announces a virtual investor event on January 6, 2025, to present updated Phase 2 data for lonigutamab, a treatment for Thyroid Eye Disease (TED), and discuss the Phase 3 LONGITUDE program. The event will include insights from leading clinicians and a Q&A session.

Sickle cell disease impacts health severely. J&J reports positive Phase III NSCLC trial results. BIAL completes full dose regimen in Parkinson’s trial. Acelyrin's stock drops despite positive Phase II data. Metsera announces positive Phase IIa GLP-1RA results. Study finds Lyme disease patients excluded by trial criteria. Denali's ALS therapy fails Phase II/III. FDA issues draft guidance on skin biopsies. CytoMed and SunAct to trial solid tumour treatment. I-Mab pauses CD73 antibody development.

ACELYRIN, INC. announced a virtual investor event on January 6, 2025, to present updated Phase 2 data for lonigutamab in Thyroid Eye Disease (TED), highlighting its efficacy and safety. The event will also discuss the Phase 3 LONGITUDE program design and feature insights from external clinicians. Lonigutamab, a subcutaneous monoclonal antibody targeting IGF-1R, shows potential for improved treatment in TED.

Lonigutamab shows potential for efficacy in Thyroid Eye Disease (TED) with a favorable safety profile. Phase 3 trials, LONGITUDE-1 and LONGITUDE-2, are set to begin in Q1 2025, with topline data expected in late 2026. The trials aim to evaluate lonigutamab's safety and efficacy, focusing on proptosis response rate at 24 weeks.

SLRN stock hits a 52-week low at $3.06, with an RSI indicating oversold conditions. Despite a strong liquidity position, the stock has seen a 1-year decline of -56.43%. Acelyrin Inc. faces challenges with its Phase 2b/3 study of izokibep but maintains a cash runway into mid-2027. TD Cowen rates Acelyrin a Buy, citing progress in its lonafarnib program. Acelyrin also updated its year-end cash guidance and plans to acquire lonigutamab rights.

The phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet the primary endpoint of statistically significant improvement in time to treatment failure versus placebo at 24 weeks. ACELYRIN will not invest further in izokibep development, focusing instead on lonigutamab for thyroid eye disease.

Acelyrin, Inc., a clinical biopharma company, specializes in developing transformative medicines, with izokibep, its lead product, in Phase 3 trials for Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, and Phase 2 for Axial Spondyloarthritis.

Acelyrin discontinues izokibep development after failed Phase IIb/III uveitis trial, following earlier failures and dosing errors. The company will focus on lonigutamab for thyroid eye disease.

The Phase 2b/3 trial of izokibep in non-infectious, non-anterior uveitis did not meet its primary endpoint of statistically significant improvement in time to treatment failure versus placebo at 24 weeks. ACELYRIN will not invest further in izokibep development, focusing instead on subcutaneous lonigutamab for thyroid eye disease.

ACELYRIN, Inc.'s shares dropped over 17% after its Phase 2b/3 trial of Izokibep for uveitis failed to meet primary and secondary endpoints. The company now focuses on Lonigutamab for thyroid eye disease, with a Phase 3 program set for 2025. ACELYRIN has a strong financial position to support its pipeline through mid-2027.